Research & Development
Overview
Promis Diagnostics is focused on validating our proprietary cancer assay via clinical research studies and plan on launching the cancer diagnostic service soon, then expanding to new products and indications. Utilizing a proprietary marker with LTE-qMSP platform, Promis Diagnostics builds its pipeline of diagnostic products for the early detection of other cancers.
Bladder Cancer
90%
Sensitivity
94%
Specificity
Promis Diagnostics’ bladder cancer test is a urine test, aimed at early detection of bladder cancer in patients. This test is a non-invasive method to analyze tumor markers in the urine of patients with hematuria and to identify patients at both low and high risk of bladder cancer. Our real time PCR-based methylation assay is a promising test to early detection of bladder cancer.
Promis Diagnostics’ colon cancer test is a stool-based test for screening and diagnosis of cancer. The assay is designed to be an easy, accurate, and affordable early colorectal cancer detection test. The test detects methylation of DNA specific to adenomatous polyps and colon cancer. In a clinical study, our colon test gave an overall sensitivity of 90.2% with a specificity of 90.2%.
Colon Cancer
90%
Sensitivity
90%
Specificity
Lung Cancer
78%
Sensitivity
92%
Specificity
Promis Diagnostic’s lung cancer test is a blood test to identify people with a heightened risk of lung cancer for triage into CT scanning. The test is a qualitative detection of epigenetic markers, PCDHGA12, associated with lung cancer in pulmonary nodule patients. It has been proven to diagnose lung cancer with 77.8% sensitivity and specificity of 92.3% in a pivotal study on 522 subjects.
DNA Methylation
High detection stability in body fluids DNA is more stable than protein and RNA.
Possible to amplify by PCR when a minute amount of DNA Methylation Biomarkers exist in body fluids
